Antonio Emanuele Elia

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/5228113/publications.pdf

Version: 2024-02-01

53 papers	2,683 citations	218592 26 h-index	189801 50 g-index
59 all docs	59 docs citations	59 times ranked	4425 citing authors

#	Article	IF	Citations
1	Short- and long-term motor outcome ofÂSTN-DBS in Parkinsonâ€™s Disease: focus on sex differences. Neurological Sciences, 2022, 43, 1769-1781.	0.9	15
2	PMCA-Based Detection of Prions in the Olfactory Mucosa of Patients With Sporadic Creutzfeldtâ€“Jakob Disease. Frontiers in Aging Neuroscience, 2022, 14, 848991.	1.7	4
3	Cerebrospinal fluid neuropathological biomarkers in beta-propeller protein-associated neurodegeneration, with complicated parkinsonian phenotype. Parkinsonism and Related Disorders, 2022, 98, 38-40.	1.1	0
4	<scp>EIF2AK2</scp> Missense Variants Associated with Early Onset Generalized Dystonia. Annals of Neurology, 2021, 89, 485-497.	2.8	32
5	Overall Efficacy and Safety of Safinamide in Parkinsonâ€™s Disease: A Systematic Review and a Meta-analysis. Clinical Drug Investigation, 2021, 41, 321-339.	1.1	14
6	Neuro-telehealth for fragile patients in a tertiary referral neurological institute during the COVID-19 pandemic in Milan, Lombardy. Neurological Sciences, 2021, 42, 2637-2644.	0.9	18
7	Levodopaâ€“carbidopa intrajejunal infusion in Parkinsonâ€™s disease: untangling the role of age. Journal of Neurology, 2021, 268, 1728-1737.	1.8	9
8	Discrimination of MSA-P and MSA-C by RT-QuIC analysis of olfactory mucosa: the first assessment of assay reproducibility between two specialized laboratories. Molecular Neurodegeneration, 2021, 16, 82.	4.4	28
9	Parkinsonism and Nigrostriatal Damage Secondary to <scp>CSF1R</scp>â€Related Primary Microgliopathy. Movement Disorders, 2020, 35, 2360-2362.	2.2	6
10	<scp>GBAâ€Related</scp> Parkinson's Disease: Dissection of Genotypeâ€“Phenotype Correlates in a Large Italian Cohort. Movement Disorders, 2020, 35, 2106-2111.	2.2	83
11	Predictors of COVID-19 outcome in Parkinson's disease. Parkinsonism and Related Disorders, 2020, 78, 134-137.	1.1	63
12	Effects of <scp>COVID</scp>â€19 on Parkinson's Disease Clinical Features: A <scp>Communityâ€Based Caseâ€Control</scp> Study. Movement Disorders, 2020, 35, 1287-1292.	2.2	148
13	Efficient RT-QuIC seeding activity for Î±-synuclein in olfactory mucosa samples of patients with Parkinsonâ€™s disease and multiple system atrophy. Translational Neurodegeneration, 2019, 8, 24.	3.6	106
14	Prevalence of psychiatric disorders in patients with inherited or idiopathic dystonia. Parkinsonism and Related Disorders, 2018, 47, 84-85.	1.1	3
15	Mitochondrial dysfunction in fibroblasts of Multiple System Atrophy. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2018, 1864, 3588-3597.	1.8	32
16	Skin Î±-synuclein deposits differ in clinical variants of synucleinopathy: an in vivo study. Scientific Reports, 2018, 8, 14246.	1.6	75
17	Concurrent AFG3L2 and SPG7 mutations associated with syndromic parkinsonism and optic atrophy with aberrant OPA1 processing and mitochondrial network fragmentation. Human Mutation, 2018, 39, 2060-2071.	1.1	32
18	Skin Nerve Phosphorylated Î±-Synuclein Deposits in Parkinson Disease With Orthostatic Hypotension. Journal of Neuropathology and Experimental Neurology, 2018, 77, 942-949.	0.9	40

#	Article	IF	Citations
19	Psychosocial difficulties in patients with Parkinsonâ€™s disease. International Journal of Rehabilitation Research, 2017, 40, 112-118.	0.7	13
20	Sensory trick in task-specific tremor. Neurological Sciences, 2017, 38, 1341-1342.	0.9	5
21	Rare causes of early-onset dystonia-parkinsonism with cognitive impairment: a de novo PSEN-1 mutation. Neurogenetics, 2017, 18, 175-178.	0.7	23
22	Patient Affected by Beta-Propeller Protein-Associated Neurodegeneration: A Therapeutic Attempt with Iron Chelation Therapy. Frontiers in Neurology, 2017, 8, 385.	1.1	18
23	Mutational analysis of COQ2 in patients with MSA in Italy. Neurobiology of Aging, 2016, 45, 213.e1-213.e2.	1.5	25
24	Quantitative gait analysis in parkin disease: Possible role of dystonia. Movement Disorders, 2016, 31, 1720-1728.	2.2	26
25	Tauroursodeoxycholic acid in the treatment of patients with amyotrophic lateral sclerosis. European Journal of Neurology, 2016, 23, 45-52.	1.7	175
26	Reply to Dr MichaudetÂal.. European Journal of Neurology, 2015, 22, e78-e78.	1.7	0
27	Causes of withdrawal of duodenal levodopa infusion in advanced Parkinson disease. Neurology, 2015, 84, 1669-1672.	1.5	35
28	Substantia nigra in Parkinsonâ€™s disease: a multimodal MRI comparison between early and advanced stages of the disease. Neurological Sciences, 2014, 35, 753-758.	0.9	50
29	Isolated limb dystonia as presenting feature of Parkin disease. Journal of Neurology, Neurosurgery and Psychiatry, 2014, 85, 827-828.	0.9	91
30	Different mutations at V363 MAPT codon are associated with atypical clinical phenotypes and show unusual structural and functional features. Neurobiology of Aging, 2014, 35, 408-417.	1.5	36
31	Clinical and polygraphic study of familial paroxysmal kinesigenic dyskinesia with PRRT2 mutation. Epileptic Disorders, 2013, 15, 123-127.	0.7	11
32	Alphaâ€synuclein gene duplication: Marked intrafamilial variability in two novel pedigrees. Movement Disorders, 2013, 28, 813-817.	2.2	29
33	Motor features and response to oral levodopa in patients with Parkinsonâ€™s disease under continuous dopaminergic infusion or deep brain stimulation. European Journal of Neurology, 2012, 19, 76-83.	1.7	31
34	Telethermographic findings after uncomplicated and septic total knee replacement. Knee, 2012, 19, 193-197.	0.8	28
35	EFNS guidelines on diagnosis and treatment of primary dystonias. European Journal of Neurology, 2011, 18, 5-18.	1.7	350
36	Response to letter by Dr Neil Murray. European Journal of Neurology, 2011, 18, e62-e62.	1.7	0

#	Article	IF	Citations
37	In vivo evidence for GABA_A receptor changes in the sensorimotor system in primary dystonia. Movement Disorders, 2011, 26, 852-857.	2.2	61
38	Low-Voltage Bilateral Pallidal Stimulation for Severe Meige Syndrome in a Patient With Primary Segmental Dystonia. Operative Neurosurgery, 2010, 67, onsE308.	0.4	14
39	Differential diagnosis of dystonia. European Journal of Neurology, 2010, 17, 1-8.	1.7	21
40	Emerging parkinsonian phenotypes. Revue Neurologique, 2010, 166, 834-840.	0.6	3
41	Botulinum neurotoxins for postâ€stroke spasticity in adults: A systematic review. Movement Disorders, 2009, 24, 801-812.	2.2	98
42	Botulinum toxin for the management of adult patients with upper motor neuron syndrome. Toxicon, 2009, 54, 634-638.	0.8	21
43	PINK1heterozygous rare variants: prevalence, significance and phenotypic spectrum. Human Mutation, 2008, 29, 565-565.	1.1	74
44	Normal cardiovascular reflex testing in patients withparkin disease. Movement Disorders, 2007, 22, 528-532.	2.2	8
45	Dystonia gravidarum: A new case with a long follow-up. Movement Disorders, 2007, 22, 564-566.	2.2	12
46	Onset and progression of primary torsion dystonia in sporadic and familial cases. European Journal of Neurology, 2006, 13, 1083-1088.	1.7	15
47	Punding and computer addiction in Parkinson's disease. Movement Disorders, 2006, 21, 1217-1218.	2.2	35
48	Frequency and phenotypes of LRRK2 G2019S mutation in Italian patients with Parkinson's disease. Movement Disorders, 2006, 21, 1232-1235.	2.2	28
49	Non-DYT1 early-onset primary torsion dystonia: Comparison with DYT1 phenotype and review of the literature. Movement Disorders, 2006, 21, 1411-1418.	2.2	37
50	The PINK1 phenotype can be indistinguishable from idiopathic Parkinson disease. Neurology, 2005, 64, 1958-1960.	1.5	81
51	PINK1 mutations are associated with sporadic early-onset parkinsonism. Annals of Neurology, 2004, 56, 336-341.	2.8	447
52	Phenotypic characterisation of autosomal recessive PARK6-linked parkinsonism in three unrelated Italian families. Movement Disorders, 2001, 16, 999-1006.	2.2	65
53	Amyotrophic onset in GCH1 dopa-responsive dystonia. Current Journal of Neurology, 0, , .	0.0	1